title: Peripheral neuropathy in rats exposed to dichloroacetate.
abstract: The use of dichloroacetate (DCA) for treating patients with mitochondrial diseases is limited by the induction of peripheral neuropathy. The mechanisms of DCA-induced neuropathy are not known. Oral DCA treatment (50-500 mg/kg per day for up to 16 weeks) induced tactile allodynia in both juvenile and adult rats; concurrent thermal hypoalgesia developed at higher doses. Both juvenile and adult rats treated with DCA developed nerve conduction slowing that was more pronounced in adult rats. No overt axonal or glial cell abnormalities were identified in peripheral nerves or spinal cord of any DCA-treated rat, but morphometric analysis identified a reduction of mean axonal caliber of peripheral nerve myelinated fibers. Dichloroacetate treatment also caused accumulation of oxidative stress markers in the nerves. These data indicate that behavioral, functional, and structural indices of peripheral neuropathy may be induced in both juvenile and adult rats treated with DCA at doses similar to those in clinical use. Dichloroacetate-induced peripheral neuropathy primarily afflicts axons and involves both metabolic and structural disorders. The DCA-treated rat may provide insight into the pathogenesis of this peripheral neuropathy and facilitate development of adjuvant therapeutics to prevent this disorder that currently restricts the clinical use of DCA.
authors.affiliation: Department of Pathology, University of California San Diego, La Jolla, California, USA. ncalcutt@ucsd.edu
authors.forename: Nigel A
authors.initials: NA
authors.lastname: Calcutt
authors.forename: Veronica L
authors.initials: VL
authors.lastname: Lopez
authors.forename: Arjel D
authors.initials: AD
authors.lastname: Bautista
authors.forename: Leah M
authors.initials: LM
authors.lastname: Mizisin
authors.forename: Brenda R
authors.initials: BR
authors.lastname: Torres
authors.forename: Albert L
authors.initials: AL
authors.lastname: Shroads
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Mizisin
authors.forename: Peter W
authors.initials: PW
authors.lastname: Stacpoole
mesh_terms: D000367:Age Factors; D000818:Animals; D003999:Dichloroacetic Acid / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004576:Electromyography; D005260:Female; D005528:Foot / Q000294:innervation; D006987:Hypesthesia / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000294:innervation
chemical_list: D003999:Dichloroacetic Acid
references.citation: Muscle Nerve. 2001 Jul;24(7):916-24
references.pmid: 11410919
references.citation: Nat Clin Pract Neurol. 2007 Mar;3(3):162-72
references.pmid: 17342192
references.citation: Toxicol Appl Pharmacol. 1981 Feb;57(2):273-87
references.pmid: 7222043
references.citation: J Neurochem. 2007 Jan;100(2):429-36
references.pmid: 17241159
references.citation: Diabetes. 2004 Jul;53(7):1807-12
references.pmid: 15220205
references.citation: Pediatrics. 2006 May;117(5):1519-31
references.pmid: 16651305
references.citation: Diabetes. 1997 Apr;46(4):647-52
references.pmid: 9075806
references.citation: Mitochondrion. 2006 Jun;6(3):126-35
references.pmid: 16725381
references.citation: J Pharmacol Exp Ther. 2008 Mar;324(3):1163-71
references.pmid: 18096758
references.citation: Diabetologia. 1976 Dec;12(6):539-46
references.pmid: 137157
references.citation: Fundam Appl Toxicol. 1990 Feb;14(2):327-37
references.pmid: 2318357
references.citation: Nature. 2007 Mar 29;446(7135):474-5
references.pmid: 17392750
references.citation: Fundam Appl Toxicol. 1991 Aug;17(2):376-89
references.pmid: 1765225
references.citation: N Engl J Med. 1978 Mar 9;298(10):526-30
references.pmid: 625308
references.citation: Neurology. 2006 Feb 14;66(3):324-30
references.pmid: 16476929
references.citation: Cancer Cell. 2007 Jan;11(1):37-51
references.pmid: 17222789
references.citation: Toxicology. 1996 Dec 18;114(3):207-21
references.pmid: 8980710
references.citation: Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1478-87
references.pmid: 18647626
references.citation: J Pharmacol Exp Ther. 1982 Aug;222(2):501-8
references.pmid: 7097569
references.citation: N Engl J Med. 1992 Nov 26;327(22):1564-9
references.pmid: 1435883
references.citation: J Neurosci Methods. 1994 Jul;53(1):55-63
references.pmid: 7990513
references.citation: N Engl J Med. 1979 Feb 15;300(7):372
references.pmid: 215910
references.citation: Metabolism. 2008 Jul;57(7):873-81
references.pmid: 18555826
references.citation: Neurosci Lett. 2008 Sep 19;442(3):267-72
references.pmid: 18619518
references.citation: Cancer Chemother Rep. 1966 May;50(4):219-44
references.pmid: 4957125
references.citation: Acta Anat (Basel). 1958;33(1-2):1-37
references.pmid: 13532246
references.citation: Pediatrics. 2008 May;121(5):e1223-8
references.pmid: 18411236
references.citation: Biochim Biophys Acta. 2007 Jul;1772(7):718-36
references.pmid: 17570293
references.citation: Acta Histochem. 2008;110(5):351-62
references.pmid: 18384843
references.citation: J Pharmacol Exp Ther. 2006 Nov;319(2):703-9
references.pmid: 16857724
references.citation: Brain Res. 1992 Mar 20;575(2):320-4
references.pmid: 1571789
references.citation: Anal Biochem. 1995 Jul 1;228(2):294-8
references.pmid: 8572309
references.citation: J Neuropathol Exp Neurol. 1999 Jun;58(6):628-36
references.pmid: 10374753
references.citation: J Neurochem. 2008 Sep;106(5):2068-79
references.pmid: 18665889
references.citation: Methods Mol Med. 2004;99:55-65
references.pmid: 15131329
references.citation: Pain. 1996 Nov;68(1):141-150
references.pmid: 9252009